BSE - Delayed Quote INR
Ambalal Sarabhai Enterprises Limited (AMBALALSA.BO)
35.20
-0.18
(-0.51%)
At close: May 9 at 3:29:16 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,850,907
1,729,437
1,696,350
1,948,893
1,624,167
Cost of Revenue
1,131,337
1,087,553
1,074,291
1,191,022
1,034,805
Gross Profit
719,570
641,884
622,059
757,871
589,362
Operating Expense
642,993
589,495
551,472
520,162
530,094
Operating Income
76,577
52,389
70,587
237,709
59,268
Net Non Operating Interest Income Expense
-46,776
-42,315
483
-6,392
-20,923
Pretax Income
144,460
66,510
151,721
541,935
325,407
Tax Provision
9,591
9,703
37,242
69,751
31,872
Net Income Common Stockholders
134,868
56,807
114,474
472,185
293,552
Diluted NI Available to Com Stockholders
134,868
56,807
114,474
472,185
293,552
Basic EPS
1.76
0.74
1.49
6.16
3.83
Diluted EPS
1.76
0.74
1.49
6.16
3.83
Basic Average Shares
76,455.72
76,633.30
76,633.30
76,633.30
76,633.30
Diluted Average Shares
76,455.72
76,633.30
76,633.30
76,633.30
76,633.30
Rent Expense Supplemental
--
4,156
6,011
9,561
18,321
Total Expenses
1,774,330
1,677,048
1,625,763
1,711,184
1,564,899
Net Income from Continuing & Discontinued Operation
134,868
56,807
114,474
472,185
293,552
Normalized Income
134,910.01
56,976.70
119,319.30
352,807.28
159,281.63
Interest Income
--
18,574
27,569
14,024
11,059
Interest Expense
61,485
57,024
23,873
16,725
27,121
Net Interest Income
-46,776
-42,315
483
-6,392
-20,923
EBIT
205,945
123,534
175,594
558,660
352,528
EBITDA
238,297
159,281
203,145
581,845
376,643
Reconciled Cost of Revenue
1,131,337
1,087,553
1,074,291
1,191,022
1,034,805
Reconciled Depreciation
32,352
35,747
27,551
23,185
24,115
Net Income from Continuing Operation Net Minority Interest
134,868
56,807
114,474
472,185
293,552
Total Unusual Items Excluding Goodwill
-45
-45
-5,561
137,104
148,842
Total Unusual Items
91
91
-5,561
137,185
148,842
Normalized EBITDA
238,206
159,190
208,706
444,660
227,801
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2.99
-11.30
-715.70
17,645.28
14,571.63
3/31/2021 - 12/30/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BDH.BO BDH Industries Limited
268.95
-0.35%
GENNEX.BO Gennex Laboratories Limited
12.07
-3.98%
MOREPENLAB.BO Morepen Laboratories Limited
56.23
-2.02%
STAR.BO Strides Pharma Science Limited
638.00
+0.60%
SYNCOMF.BO Syncom Formulations (India) Limited
15.05
-2.71%
ZYDUSLIFE.BO Zydus Lifesciences Limited
877.90
+0.69%
NEULANDLAB.NS Neuland Laboratories Limited
12,429.00
+0.85%
WOCKPHARMA.NS Wockhardt Limited
1,224.30
-0.88%
AARTIDRUGS.NS Aarti Drugs Limited
418.65
+0.22%
KNSA Kiniksa Pharmaceuticals International, plc
26.03
-2.58%